PRA Health Sciences announced that Symphony Health, a PRA Health Sciences company, will make a 30-day license of its newly released Metys Covid-19 Module available to the United States (US) life science industry at no charge.
The Covid-19 Module within the Metys platform will provide up to three users per company with access to all drugs and markets within any US geographic region down to CBSA (core-based statistical area).
The module will include history back to October 2018 to ensure access to comparative flu season trends in prior years, with March 2020 data becoming available on April 10. Companies may publish or report insights or findings from the data with prior permission from Symphony.
The President of Symphony Health, Doug Fulling said, Covid-19 has delivered an unprecedented challenge to the life sciences industry in the US and beyond.
“As we mobilize to fight Covid-19, those in life sciences can use the data and insights available to see trends, to react quickly and then plan for the future.
“We are hoping this level of insight from one of the most robust databases in the U.S. market benefits not only our clients and their patients, but also society as a whole,” he said in a statement.
